Monitoring and Regulating Offshore Stem Cell Clinics-Reference-Cited by-同舟云学术

Monitoring and Regulating Offshore Stem Cell Clinics

Published:2009-03-20 Issue:5921 Volume:323 Page:1564-1565
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Kiatpongsan Sorapop¹²³,Sipp Douglas⁴⁵

Affiliation:

1. Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 10330.

2. Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA.

3. Science, Technology and Globalization Project/Science, Technology and Public Policy Program, Belfer Center for Science and International Affairs, John F. Kennedy School of Government, Harvard University, Cambridge, MA 02138, USA.

4. RIKEN Center for Developmental Biology, Kobe, 650-0047, Japan.

5. Center for iPS Research and Application, Institute for Integrated Cell-Materials Sciences, Kyoto University, Kyoto, 606-8501, Japan.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference33 articles.

1. Amariglio N., et al., PLoS Med.6, (2009)e29.

2. Lau D., et al., Cell Stem Cell3, 591 (2008).

3. International Society for Stem Cell Research, Guidelines for the Clinical Translation of Stem Cells (ISSCR, Deerfield, IL, 4 December 2008)(http://www.isscr.org/clinical_trans/.

4. Juvenile Diabetes Research Foundation International Participating in a Clinical Trial ; www.jdrf.org/index.cfm?fuseaction=home.viewPage&page_id=91EC2BF7-1321-C844-134D2E25FB931863.

5. Einhorn B. Veale J. Kripalani M. Business Week 10 January 2005 p. 34; www.businessweek.com/magazine/content/05_02/b3915052.htm.

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era;Cytotherapy;2024-04

2. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies;Regenerative Medicine;2023-10-23

3. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine;BMC Medicine;2022-12-27

4. Creative regulatory practices to develop stem-cell technology: the way forward for Malaysia;Regenerative Medicine;2022-02

5. The Importance of Evidence Based Practices and Autism;Handbook of Autism and Pervasive Developmental Disorder;2022